Subscribe To
POLBF / Poolbeg Pharma inks clinical trial agreement for influenza asset
POLBF News
By Proactive Investors
November 3, 2023
Poolbeg's lead asset to be in the spotlight at leading medical conference
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste more_horizontal
By Proactive Investors
November 1, 2023
Poolbeg investor meeting will take a deep dive into lead programme
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin more_horizontal
By Proactive Investors
October 26, 2023
Poolbeg advisory board endorses flu drug approach
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has secured an endorsement from its scientific advisory board (SAB) of the prioritised targets for more_horizontal
By Proactive Investors
October 17, 2023
Poolbeg Pharma up 8% on deal with Nasdaq biotech
Shares in Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) rose 8% in early trading after the company announced a partnership with an unnamed Nasdaq-listed more_horizontal
By Proactive Investors
October 17, 2023
Poolbeg Pharma inks collaboration agreement with Nasdaq biotech
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has inked an agreement with an unnamed Nasdaq-listed biopharmaceutical entity aimed at developing more_horizontal
By Proactive Investors
September 29, 2023
Poolbeg Pharma closes chapter on patent challenge
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical group, has announced the cancellation of the European Patent Office ( more_horizontal
By Proactive Investors
September 20, 2023
Poolbeg Pharma shores up protection around its IP
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical firm, recently received a notice of allowance from the Japanese Paten more_horizontal
By Proactive Investors
September 19, 2023
Poolbeg Pharma: Third party withdraws patent opposition
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said that an unnamed 'third party' has agreed to withdraw its opposition to one of the company's European more_horizontal